Recommendations from the United European Gastroenterology evidence-based guidelines for the diagnosis and therapy of chronic pancreatitis

…, P Fockens, A Drewes, GO Cheyan, JP Drenth… - Pancreatology, 2018 - Elsevier
Background In collaboration with United European Gastroenterology, the working group on ‘Harmonizing
diagnosis and treatment of chronic pancreatitis across Europe’ (HaPanEU) …

Population-based epidemiology, malignancy risk, and outcome of primary sclerosing cholangitis

…, AC Poen, KM van Nieuwkerk, JP Drenth… - Hepatology, 2013 - journals.lww.com
Extensive population-based studies are much needed to accurately establish epidemiology
and disease course in patients with primary sclerosing cholangitis (PSC). We aimed to …

Endurance run increases circulating IL-6 and IL-1ra but downregulates ex vivo TNF-alpha and IL-1 beta production

JP Drenth, SH Van Uum… - Journal of applied …, 1995 - journals.physiology.org
This investigation determined the manner in which the cardiovascular system copes with the
dehydration-induced reductions in cardiac output (Q) during prolonged exercise in the heat. …

[PDF][PDF] United European Gastroenterology evidence-based guidelines for the diagnosis and therapy of chronic pancreatitis (HaPanEU)

…, A Drewes, G Ceyhan, B Lindkvist, JP Drenth… - 2017 - repository.ubn.ru.nl
BACKGROUND: There have been substantial improvements in the management of chronic
pancreatitis, leading to the publication of several national guidelines during recent years. In …

Activation of the cytokine network in familial Mediterranean fever.

N Gang, JP Drenth, P Langevitz, D Zemer… - The Journal of …, 1999 - europepmc.org
Objective To elucidate the role of cytokines in the pathogenesis of familial Mediterranean
fever (FMF), an inherited disease characterized by attacks of serosal membrane inflammation. …

[HTML][HTML] Effect of NGM282, an FGF19 analogue, in primary sclerosing cholangitis: a multicenter, randomized, double-blind, placebo-controlled phase II trial

GM Hirschfield, O Chazouillères, JP Drenth… - Journal of …, 2019 - Elsevier
Background & Aims Primary sclerosing cholangitis (PSC) is an inflammatory, cholestatic
and progressively fibrotic liver disease devoid of effective medical intervention. NGM282, an …

Cytokine activation during attacks of the hyperimmunoglobulinemia D and periodic fever syndrome

JP Drenth, M van Deuren, J van der Ven-Jongekrijg… - 1995 - ashpublications.org
The hyperimmunoglobulinemia D and periodic fever (hyper-IgD) syndrome is typified by
recurrent febrile attacks with abdominal distress, joint involvement (arthralgias/arthritis), …

Telaprevir is effective given every 8 or 12 hours with ribavirin and peginterferon alfa-2a or-2b to patients with chronic hepatitis C

…, T Goeser, P Ferenci, F Nevens, G Carosi, JP Drenth… - Gastroenterology, 2011 - Elsevier
BACKGROUND & AIMS: Recent studies have shown that 12 weeks of treatment with telaprevir,
administered every 8 hours (q8h), combined with pegylated interferon (peginterferon) alfa…

Evaluation of (pre-) malignant colonic abnormalities: endoscopic validation of FDG-PET findings

JP Drenth, FM Nagengast, WJ Oyen - European journal of nuclear …, 2001 - Springer
The diagnostic accuracy of 2-[ 18 F]-fluoro-2-deoxy-D-glucose positron emission tomography
(FDG-PET) for the detection of (pre-)malignant lesions of the colon was compared with that …

Insulin resistance and response to telaprevir plus peginterferon α and ribavirin in treatment-naive patients infected with HCV genotype 1

…, T Goeser, P Ferenci, F Nevens, G Carosi, JP Drenth… - Gut, 2012 - gut.bmj.com
Objective Insulin resistance is a predictor of poor response to peginterferon/ribavirin in
patients infected with the chronic hepatitis C virus (HCV). There are no data on direct-acting …